213 related articles for article (PubMed ID: 31245489)
1. Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine.
Tobita M; Konomi K; Torashima Y; Kimura K; Taoka M; Kaminota M
Regen Ther; 2016 Jun; 4():78-81. PubMed ID: 31245489
[TBL] [Abstract][Full Text] [Related]
2. Regulatory perspectives of Japan.
Kusakabe T
Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
[TBL] [Abstract][Full Text] [Related]
3. Recent policies that support clinical application of induced pluripotent stem cell-based regenerative therapies.
Azuma K; Yamanaka S
Regen Ther; 2016 Jun; 4():36-47. PubMed ID: 31245486
[TBL] [Abstract][Full Text] [Related]
4. Insurance systems and reimbursement concerning research and development of regenerative medicine in Japan.
Okada K; Miyata T; Sawa Y
Regen Med; 2017 Mar; 12(2):179-186. PubMed ID: 28244828
[TBL] [Abstract][Full Text] [Related]
5. Current status of platelet-rich plasma therapy under the act on the safety of regenerative medicine in Japan.
Arita A; Tobita M
Regen Ther; 2023 Jun; 23():37-43. PubMed ID: 37063096
[TBL] [Abstract][Full Text] [Related]
6. Regulatory Frameworks for Gene and Cell Therapies in Japan.
Maeda D; Yamaguchi T; Ishizuka T; Hirata M; Takekita K; Sato D
Adv Exp Med Biol; 2015; 871():147-62. PubMed ID: 26374217
[TBL] [Abstract][Full Text] [Related]
7. [Current status of the regulation and development of cell therapy products in Japan].
Igarashi Y; Sato Y
Nihon Yakurigaku Zasshi; 2018; 151(6):254-259. PubMed ID: 29887575
[TBL] [Abstract][Full Text] [Related]
8. Consideration of and expectations for the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act in Japan.
Okada K; Koike K; Sawa Y
Regen Ther; 2015 Jun; 1():80-83. PubMed ID: 31245444
[TBL] [Abstract][Full Text] [Related]
9. Regulatory Aspects of Cell and Gene Therapy Products: The Japanese Perspective.
Maruyama Y; Noda S; Okudaira S; Sakurai A; Okura N; Honda F
Adv Exp Med Biol; 2023; 1430():155-179. PubMed ID: 37526847
[TBL] [Abstract][Full Text] [Related]
10. Impact and challenges of enactment for advanced regenerative medicine in South Korea.
Kim DS; Bae S
Front Bioeng Biotechnol; 2022; 10():972865. PubMed ID: 36312539
[TBL] [Abstract][Full Text] [Related]
11. Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.
Takashima K; Morrison M; Minari J
Stem Cell Reports; 2021 Jun; 16(6):1425-1434. PubMed ID: 34019814
[TBL] [Abstract][Full Text] [Related]
12. New Governmental Regulatory System for Stem Cell-Based Therapies in Japan.
Hara A; Sato D; Sahara Y
Ther Innov Regul Sci; 2014 Nov; 48(6):681-688. PubMed ID: 30227468
[TBL] [Abstract][Full Text] [Related]
13. New Japanese Regulatory Frameworks for Clinical Research and Marketing Authorization of Gene Therapy and Cellular Therapy Products.
Nagai S; Ozawa K
Curr Gene Ther; 2017; 17(1):17-28. PubMed ID: 28382858
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
Inokuma Y
Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
[TBL] [Abstract][Full Text] [Related]
15. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
Okada K; Sato Y; Sugiyama D; Sawa Y
Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
[TBL] [Abstract][Full Text] [Related]
16. Japanese Laws and the Current Status of Regenerative Medicine in the Tohoku Region.
Kamano Y; Terajima N; Chiba Y; Suresh VV; Saito M
J Contemp Dent Pract; 2023 Feb; 24(2):120-128. PubMed ID: 37272144
[TBL] [Abstract][Full Text] [Related]
17. Basic points to consider regarding the preparation of extracellular vesicles and their clinical applications in Japan.
Tsuchiya A; Terai S; Horiguchi I; Homma Y; Saito A; Nakamura N; Sato Y; Ochiya T; Kino-Oka M;
Regen Ther; 2022 Dec; 21():19-24. PubMed ID: 35619946
[TBL] [Abstract][Full Text] [Related]
18. Regenerative medicine legislation in Japan for fast provision of cell therapy products.
Fujita Y; Kawamoto A
Clin Pharmacol Ther; 2016 Jan; 99(1):26-9. PubMed ID: 26482927
[TBL] [Abstract][Full Text] [Related]
19. [Translational/regulatory science researches of NIHS for regenerative medicine and cellular therapy products].
Sato Y
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):6-9. PubMed ID: 25707195
[TBL] [Abstract][Full Text] [Related]
20. [Reform of Japan's NTP and its technical perspectives].
Mori T
Kekkaku; 2004 Oct; 79(10):587-604. PubMed ID: 15631111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
